Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial
Thomas Engstrøm(University of Copenhagen), Lars Køber(University of Copenhagen), Lene Holmvang(Rigshospitalet), Anton Boel Villadsen(Aalborg University Hospital), Ole De Backer(University of Copenhagen), Steffen Helqvist(Rigshospitalet), Frants Pedersen(University of Copenhagen), Henning Kelbæk(Zealand University Hospital), Dan Eik Høfsten(University of Copenhagen), Hans–Henrik Tilsted(Aalborg University Hospital), Jens Aarøe(Aalborg University Hospital), Erik Jørgensen(Massachusetts General Hospital), Kari Saunamäki(University of Copenhagen), Jan Ravkilde(Aalborg University Hospital), Peter Clemmensen(Rigshospitalet), Svend Eggert Jensen(Aalborg University Hospital), Bent Raungaard(Aalborg University Hospital), Lene Kløvgaard(Rigshospitalet)
Cited by 966
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k